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Human herpesvirus infections 
and dementia or mild cognitive 
impairment: a systematic review 
and meta-analysis
Charlotte Warren-Gash1, Harriet J. Forbes1, elizabeth Williamson1, Judith Breuer  2, 
Andrew C. Hayward3, Angelique Mavrodaris4, Basil H. Ridha5,6, Martin N. Rossor5,6, 
sara L. thomas1 & Liam smeeth1
Interest is growing in the role of infectious agents in the pathogenesis of dementia, but current evidence 
is limited. We conducted a systematic review and meta-analysis to investigate the effect of any of eight 
human herpesviruses on development of dementia or mild cognitive impairment (MCI). We searched 
the Cochrane Library, embase, Global Health, Medline, psycINFo, scopus, Web of science, clinical trials 
registers and grey literature sources from inception to December 2017 for observational studies with 
cohort, case control or self-controlled designs, or randomised controlled trials of interventions against 
herpesviruses. Pooled effect estimates and 95% confidence intervals (CIs) were generated through 
random effects meta-analyses across studies with the same design, outcome, and virus type, method 
and site of measurement. We included 57 studies across various geographic settings. Past infection 
with herpesviruses, measured by IgG seropositivity, was generally not associated with dementia risk. 
A single cohort study rated moderate quality showed an association between varicella zoster virus 
reactivation (ophthalmic zoster) and incident dementia (HR 2.97; 95%CI, 1.89 to 4.66). Recent infection 
with, or reactivation of, herpes simplex virus type 1 or type 1/2 unspecified, cytomegalovirus and 
human herpes virus-6 measured by serum IgM, high titre IgG or clinical disease may be associated with 
dementia or MCI, though results were inconsistent across studies and overall evidence rated very low 
quality. Longitudinal population studies with robust repeated virus measurements taken sufficiently 
proximal to dementia onset are needed to establish whether, when and among whom herpesviruses 
affect dementia risk.
Whether chronic viral infections increase the risk of dementia remains controversial: despite decades of research, 
high-quality population studies are lacking. Nevertheless, only around one third of dementia cases are due to 
modifiable risk factors1. This, combined with the projected 2.8-fold increase in the global burden of dementia 
to 131.5 million cases by 20502, and the lack of effective treatments, has added impetus to the search for novel 
modifiable risk factors.
Infections with a systemic inflammatory component can trigger brain responses through microglial activation 
and release of pro-inflammatory mediators3. Chronic antigenic stimulation may also contribute to age-associated 
immune system remodelling and accelerate neurodegeneration in disorders such as dementia4,5. In neuronal and 
glial cell cultures, herpes simplex virus type 1 (HSV-1) – one of eight herpesviruses that routinely infects humans 
– induces molecular changes similar to those seen in Alzheimer’s disease (AD), e.g. β-amyloid accumulation6, 
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generation of amyloid precursor protein fragments with neurotoxic potential7, and tau hyperphosphorylation8. It 
remains unclear, however, whether HSV-1 has similar effects in vivo.
A previous meta-analysis of small case-control studies of varying quality, with heterogeneous methods of her-
pesvirus detection and dementia diagnosis, suggested tentative associations between HSV-1 and AD (pooled OR 
1.38; 95%CI, 1.03–1.84) and Epstein-Barr virus (EBV) and AD (pooled OR 1.55; 95%CI, 1.12–2.13)9. However, 
interpretation is challenging as data were pooled across studies detecting herpesviruses from different body sites; 
past infections were not differentiated from recent infections, nor primary infection from virus reactivation. Here, 
we systematically reviewed literature on infection with, or reactivation of, any of the eight human herpesviruses 
and risk of developing dementia or mild cognitive impairment (MCI).
Methods
This systematic review and meta-analysis was performed in accordance with PRISMA guidelines10, and reg-
istered with the International Prospective Register of Systematic Reviews on 7 January 2017 (Registration no: 
CRD42017054684).
search strategy. We searched the Cochrane Library, Embase, Global Health, Medline, PsycINFO, Scopus, 
Web of Science and grey literature sources for articles in any language reporting associations between any human 
herpesvirus and dementia or MCI in adults in any setting. Searches were conducted from database inception to 
7 March 2017. Upon identifying a key paper published after this date, we repeated searches in 7 December 2017 
limited to the years 2016 and 2017 (see data supplement for full search strategy).
study selection. We included studies of infection with, reactivation of, and where relevant, vaccination 
against or treatment of, HSV-1, HSV-2, varicella zoster virus (VZV), EBV, cytomegalovirus (CMV) and human 
herpesviruses types 6, 7 and 8 (HHV-6,-7,-8), defined by clinical or laboratory criteria. Primary outcomes were 
dementia (all types) and MCI. We included randomised controlled trials (RCTs), cohort, case-control, case 
crossover and self-controlled case series studies with sufficient data to calculate effect estimates. A detailed pro-
tocol is published elsewhere11. Two reviewers (HJF, CWG) scanned all titles and abstracts in parallel to select 
full-text manuscripts for review. Full-text manuscripts were then reviewed in parallel and reasons for exclusion 
recorded. A third reviewer (LS) resolved any discrepancies. Where relevant, we emailed authors to obtain missing 
information.
Data extraction. Two reviewers (HJF, CWG) extracted data according to a standardised data extraction 
template in parallel for the first three studies, then one reviewer (HJF) extracted data for remaining studies. We 
included information on author, year, design, setting, study population, and definition and ascertainment of 
exposures, outcomes and comparators. We also extracted population size, follow up time, number of subjects 
with the outcome (or exposure for case-control studies), statistical methods, main results and sub-group analyses. 
Where only raw data were reported, we calculated unadjusted effect estimates and 95% confidence intervals using 
appropriate online calculators.
Risk of bias and quality assessment. Risk of bias was assessed in line with the Cochrane collaboration 
approach12,13. For observational studies, we considered biases due to confounding, participant selection, misclas-
sification of variables, missing data and reverse causation. For the intervention study, we included domains rel-
evant to RCTs (selection bias, performance bias, detection bias, attrition bias and reporting bias). Two reviewers 
assessed risk of bias in parallel for the first three studies, and then one reviewer assessed the remaining studies. We 
classified each domain as ‘High’, ‘Moderate’, ‘Low’ or ‘Unclear’ risk and, in a sensitivity analysis, removed studies 
with >one domain rated ‘High risk’. Publication bias was investigated when there were at least ten studies, using 
a funnel plot and Begg’s test14. Finally, we used Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE)15, to estimate the quality of cumulative evidence by virus exposure and outcome (see data 
supplement).
statistical analysis. Results were presented by exposure (virus type) and outcome (dementia or MCI). 
Exposures were subdivided into recent infection/reactivation (measured by viral nucleic acid, serum IgM, 
intrathecal antibody synthesis, high serum IgG titre or a recent history of clinical disease) and past infection 
(measured by IgG seropositivity). We meta-analysed data if there were at least two studies with the same outcome, 
design and detailed exposure criteria (virus type, method and site of exposure measurement). We conducted 
meta-analyses using both fixed and random effects models but presented final results from random effects mod-
els only for consistency: random effects models were judged more appropriate when there was at least moderate 
heterogeneity (I2 > 25%). Sub-group analyses e.g. by age, APOE4 status and underlying cause of dementia were 
considered where appropriate.
Results
study characteristics. Initial searches retrieved 4,526 citations, of which 136 were selected for full-text 
review and 55 included. Updated searches retrieved 480 citations, of which five full texts were reviewed and two 
additional studies included (Fig. 1). The 57 studies (43 case-control, 13 cohort, one RCT) were published between 
1974 and 2017 in various geographic settings (UK (n = 14), rest of Europe (n = 22), Far East (n = 8), USA (n = 7) 
and elsewhere/not reported (n = 6)). For 46 studies, the outcome was dementia alone (AD (n = 35), AIDS-related 
dementia (n = 5), vascular dementia (n = 2), mixed or unspecified dementia (n = 4)), five studies investigated AD 
and/or MCI, while the remaining six studies investigated MCI alone (e-table 1). Studies presented 163 estimates 
for effects of herpesviruses on dementia or MCI (119 main effects; 44 subgroup analyses: e-table 2).
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Effects of individual herpesviruses. For HSV-1, 32 case-control16–47 and three cohort studies48–50 inves-
tigated associations with dementia or MCI. Two studies had no domains at high risk of bias49,50, three had one 
domain38,43,48 and 30 had ≥two domains at high risk of bias (e-table 3). Seventeen post-mortem case-control stud-
ies, all with at least two domains at high risk of bias, showed no evidence of a difference in detection of HSV-1 in the 
brains of dementia patients compared to controls: pooled OR 1.31; 95%CI, 0.90–1.90, though 14 of 17 studies had 
<100 participants. There was also no association between HSV1 DNA in lymphocytes (two studies)22,24, intrath-
ecal HSV1 antibody synthesis (one study)36, HSV1 IgG seropositivity (eight studies)25,32,33,38,44,47–49 or IgG sub-
classes (one study)31 and dementia. One case-control study suggested HSV1 IgG titres were higher in AD patients 
than controls (adjusted OR 1.22; 95%CI, 1.04–1.43)20 and in a secondary analysis of another case-control study, 
high-titre serum IgG was associated with dementia: OR 2.87; 95%CI, 1.14–7.2232 (Fig. 2). For MCI, case-control 
studies showed no association with HSV-1 IgG seropositivity (three studies)25,33,47, HSV-1 IgG subclasses (one 
study)31, or HSV-1 detection in blood (method unspecified; one study)39 (e-Fig. 1). A population cohort with no 
domains at high risk of bias also showed no association between rates of cognitive decline over 4 years and HSV-1 
baseline antibody titre50.
The effect of HSV-1/2 (type unspecified) was assessed in a further five case-control51–55 and three cohort 
studies56–58. Three had no domains at high risk of bias53,57,58, one had one domain56 and four studies had multiple 
domains at high risk of bias51,52,54,55. Results were mixed; HSV-1/2 in the brain was not associated with dementia 
in two small post-mortem case-control studies (pooled OR 1.54; 95%CI, 0.18–13.38) (overall n = 71)51,54. Serum 
IgM showed an association with dementia in three cohort studies (pooled OR 1·73; 95%CI, 1.12–2.68) with 0–1 
domain at high risk of bias56–58 but a case-control study found no effect53. IgG seropositivity to HSV-1/2 was 
not associated with dementia in two cohort studies (pooled OR 1.18; 95%CI, 0.73–1.92)56,57 but had a marginal 
association in two case-control studies (pooled OR 2.53; 95%CI, 1.01–6.34)52,53 (Fig. 3). One study found no 
difference in mean HSV-1/2 serum antibody titres between dementia cases and controls (effect estimates not 
reported)55.
For HSV-2, there were three case-control studies29,39,42, all with ≥two domains at high risk of bias. There was 
no association between HSV-2 virus detected in the brain and dementia in two studies: pooled OR 0.53; 95%CI, 
0.18–1.5629,42, while the third showed an association between HSV-2 (measurement unspecified) in blood and 
vascular MCI: unadjusted OR 4.29; 95%CI, 2.01-9.1639 (Fig. 3).
The relationship between VZV and dementia was explored in one cohort study59, with no domains at high 
risk of bias, and five case-control studies27,40,44,46,52, all with ≥two domains at high risk of bias. The cohort study 
showed a very strong association between ophthalmic zoster (VZV reactivation) and dementia: adjusted HR 
2.97; 95%CI, 1.89-4.6659. Neither VZV DNA detected in post-mortem brain samples in two case-control studies 
(pooled OR 0.79; 95%CI, 0.23–2.77)27,40 nor VZV IgG serum antibodies from two other case-control studies 
(pooled OR 0.67; 95%CI, 0.38–1.17) was associated with dementia44,52 (Fig. 4). One additional case-control study 
reported no association between serum IgG reactivity and AD but did not present estimates46.
For EBV, there were three case-control studies42,44,60, each with ≥two domains at high risk of bias. EBV DNA 
in the brain was not associated with dementia in one small study of post-mortem brains (n = 10): OR 1.00; 95%CI, 
0.02–59.9342, while another study showed a marginal association between EBV DNA in the blood and dementia: 
unadjusted OR 1.46; 95%CI, 1.01–2.1160. The third study found that serum antibodies to three EBV antigens were 
not associated with dementia44 (Fig. 4). One additional nested case-control study with one domain at high risk of 
bias showed an increase in EBV IgG levels among those developing MCI over two year follow-up (p = 0.003)43.
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Figure 1. Flow diagram of study selection.
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Associations between CMV and dementia or MCI were investigated in 17 case-control29,30,32,38–41,44–47,52,55,60–63 
and three cohort studies49,50,64. Four studies had no domains at high risk of bias49,50,63,64, one had one domain38 and 
15/20 had ≥two domains at high risk of bias. Neither CMV DNA in the brain (pooled OR from four case-control 
studies 2.25; 95%CI, 0.55–9.24)29,41,42,45, CMV-specific serum IgG (pooled OR from eight case-control studies 
1.30; 95%CI, 0.65–2.63)32,38,44,47,52,61–63, nor high CMV antibody titres (one case-control study)32 were associated 
with dementia. Three additional case-control studies compared blood CMV IgG titres between dementia cases 
and controls but did not present effect estimates; two reported no difference46,55 and one found that AD patients 
had higher mean antibody titres than controls (p = 0.014)60. CMV IgG seropositivity at baseline was associated 
with AD in one cohort with no domains at high risk of bias: RR 2.15; 95%CI, 1.42–3.2749 (Fig. 5). For MCI, one 
large Mexican-American population cohort with no domains at high risk of bias reported a decline in MMSE 
score associated with a one unit increase in serum CMV IgG titre (p < 0.001) and a marked difference between 
MMSE scores of participants with the highest and lowest antibody titres (p = 0.003)50. In contrast, a smaller 
Japanese community cohort study, also with no domains at high risk of bias, showed no association between 
quartiles of CMV titre and cognitive function64. One case-control study found no association between IgG sero-
positivity and MCI47 while another case-control study reported that CMV in blood (detection method unclear) 
was associated with MCI in unadjusted analysis: OR 2.17; 95%CI, 1.28–3.6739.
The relationship between HHV-6 and dementia or MCI was explored in eight case-control stud-
ies29,30,36,40,41,46,47,60, all with ≥two domains at high risk of bias and one cohort study, which had one domain at 
high risk of bias48. HHV-6 DNA detection in the brain was associated with dementia in three case-control studies: 
pooled OR 2.47; 95%CI, 1.25–4.8629,30,40, and HHV-6 DNA in blood had a marginal association with dementia in 
data pooled across two further case-control studies: pooled OR 1.22; 95%CI, 1.01–1.4746,60. There was no asso-
ciation between HHV-6 intrathecal antibody synthesis and dementia in two case-control studies36,47, or between 
HHV-6 IgG seropositivity and dementia in the cohort study48 (e-Fig. 2). One case-control study suggested a neg-
ative association between HHV6 seropositivity and MCI: OR 0.32; 95%CI, 0.11–0.9747.
Figure 2. Effect of herpes simplex virus type 1 infections on dementia risk. 
!! No adjustment/matching for age. One study assessing the effect of HSV1 in the brain (Lin, 1998) is not 
included here as it uses the same data as another study (Lin, 2002a); however, it has been retained for sub-group 
analyses.
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Figure 3. Effect of herpes simplex virus type 2 or herpes simplex type unspecified on dementia risk. 
!! No adjustment/matching for age.
Figure 4. Effect of varicella zoster virus and Epstein-Barr virus on dementia risk. 
!! No adjustment/matching for age.
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For HHV-8 (and/or Kaposi’s sarcoma (KS)) there were two case-control65,66 and four cohort studies67–70, all 
carried out among people with HIV. Two studies had no domains at high risk of bias66,70, two had one domain68,69 
and two had two domains at high risk of bias65,67. HHV-8 IgG seropositivity was not associated with demen-
tia in either a case-control study: OR 1.22; 95%CI, 0.66-2.2766 or two cohort studies: pooled OR 0.79; 95%CI, 
0.37–1.6969,70, all with 0–1 domain at high risk of bias. KS was not associated with dementia in one case-control 
study65 and had weak evidence of an apparent protective effect against dementia in three cohorts: pooled OR 0.58; 
95%CI, 0.33–1.0567,68,70 (e-Fig. 2).
One cohort study, with no domains at high risk of bias, investigated the effect of infection with multiple her-
pesviruses71. IgG seropositivity to HSV-1, HSV-2 and CMV was associated with an increased risk of cognitive 
decline compared to infection with 0–1 virus: OR 2.3; 95%CI, 1.1–5.0, however having two herpesviruses com-
pared to 0–1 was not associated with cognitive decline: OR 1.8; 95%CI, 0.9–3.6.
One RCT72 and one cohort study58, each with no domains at high risk of bias, investigated the effect of antivi-
ral treatment for HSV-1 on cognition or dementia. The RCT showed that using valacyclovir for 90 days in patients 
with HSV encephalitis had no effect on cognitive sequelae at 12 months (adjusted OR 0.81; 95%CI, 0.24–2.77)72. 
The population cohort study showed that incident dementia rates were similar for people with and without reim-
bursement claims data for anti-herpetic medication: adjusted HR 0.75, no CIs presented, p = 0.1458.
In sub-group analyses, no differences by age or sex were seen in studies of HSV-1, HSV-1/2, VZV reacti-
vation or HHV-8. Several studies of HSV-1, HSV-1/2, VZV and HHV-6 stratified by APOE4 status, but there 
were no consistent patterns. Stratifying by dementia subtype gave similar effects to those presented in the main 
meta-analysis. Finally, removing studies at the highest risk of bias did not result in major differences to findings 
(e-Figs A1–A3). We did not find evidence of publication bias for studies of HSV-1 DNA in the brain and dementia 
(p = 0.88) (e-Fig. 4).
Overall, the quality of evidence for VZV reactivation on dementia was judged to be moderate, whilst for 
every other herpesvirus exposure and dementia or MCI, the quality of evidence was judged to be very low using 
GRADE criteria, due to serious or very serious risks of bias, inconsistency and imprecision (e-table 4).
Discussion
Our systematic review showed that, while past herpesvirus infection was generally not associated with dementia 
risk, there were tentative associations between recent infection with, or reactivation of, several herpesviruses and 
dementia or MCI, though quality of evidence across the 57 included studies was very low. For HSV-1, HSV-1/2, 
and HSV-2 there was no evidence that DNA in the brain was associated with dementia and little robust evidence 
that HSV-1 or HSV-1/2 IgG seropositivity was associated with the risk of dementia or MCI. Although some stud-
ies suggested that recent infection or reactivation of HSV-1/2, measured by serum IgM or high titre serum IgG, 
was associated with dementia, results were inconsistent and evidence graded very low quality. Moderate quality 
evidence from a single study indicated that clinically-diagnosed VZV reactivation (specifically ophthalmic zoster) 
Figure 5. Effect of cytomegalovirus on dementia risk. 
!! No adjustment/matching for age.
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was associated with increased risk of dementia, while VZV infection or reactivation from brain or serum samples 
was not associated with dementia. Findings for EBV and CMV were inconsistent and rated very low quality. 
Although most studies reported no association with dementia, serum IgG CMV seropositivity was associated 
with dementia in one cohort, and CMV IgG titres with rates of cognitive decline in another large population 
cohort, but not in a smaller cohort of the very old. Very low quality evidence suggested that HHV-6 recent infec-
tion/reactivation, but not past HHV-6 or HHV-8 infection, was associated with dementia risk.
Human herpesviruses establish latency and persist lifelong after initial infection. Our finding that past infec-
tion alone was insufficient to raise dementia risk is consistent with current understanding of neurotropic her-
pesvirus latency, during which viruses such as HSV-1 and VZV show very restricted gene expression and do not 
produce infective virus particles or induce clinical disease73. Virus reactivation leading to systemic inflammation, 
glial activation and neuro-inflammation is a putative mechanism to explain our finding that recent infection/
reactivation of several herpesviruses may be associated with cognitive decline or dementia74. For the most robust 
relationship identified in our review – that of ophthalmic zoster with dementia – localised vasculopathy, which 
occurs when VZV replicates in cerebral arteries75, may contribute to pathogenesis. For other viruses, potential 
mechanisms are less well-understood. While recent work showing β-amyloid seeding in response to HSV-1 and 
HHV-6 infection in mouse models and human neuronal cell cultures supports an anti-microbial peptide role for 
β-amyloid76, the significance for cognitive function in older adults is unknown. A disordered immune response to 
infections among older people, in part driven by CMV-induced immune system remodelling, has been proposed 
to promote development of inflammatory disorders such as autoimmune conditions and, potentially, dementia5.
Strengths of our review include the comprehensive search strategy covering seven medical databases as well as 
clinical trials registers and grey literature for articles in any language, setting or time period. We pre-specified and 
published our analysis plan11, which included careful consideration of methods of herpesvirus measurement to 
avoid inappropriate meta-analyses across heterogeneous exposures. Contact with authors and double reviewing 
throughout identified several instances of duplicate data published in different conference abstracts, which we 
excluded from meta-analyses. We also conducted a thorough risk of bias assessment for included studies and 
assessed the quality of evidence overall for each herpesvirus exposure to guide future research. Nevertheless, the 
strength of evidence is limited by the poor quality of many studies. This included bias associated with difficulty 
measuring herpesvirus exposures, other than past infection (denoted by serum IgG). Understanding of the nature 
of sub-clinical herpesvirus reactivation is limited and there is a dearth of standardised methods to assess viral 
activation. Even markers such as serum IgM, which is known to be associated with recent infection or reactiva-
tion, lack sensitivity. It is also unclear whether peripheral virus reactivation correlates with central nervous system 
reactivation. While some studies detected herpesvirus nucleic acid in post-mortem brains, it is unclear whether 
this reflects reactivation or peri-mortem changes associated with neurodegeneration. Our outcome definitions 
were intentionally broad and likely incorporated heterogeneous neuropathologies leading to dementia, although 
we did not see differences in results stratified by dementia sub-type. Nevertheless, a lack of consistency of demen-
tia definitions and variable reporting of clinical outcomes makes between-study comparisons challenging. In 
general, our review found a lack of longitudinal studies with repeated measures of exposure, a lack of control for 
confounding e.g. by age and sex and many small studies that were underpowered to detect an effect.
In contrast to our findings, one previous systematic review and meta-analysis of 35 studies of herpesviruses 
and dementia reported an association between any herpesvirus in the brain and AD, and specific associations 
between HSV-1 and EBV with AD9. However, the virus-specific results were pooled across any method of virus 
detection (PCR, in-situ hybridization, serum IgG, serum IgM) at any site (blood, brain or CSF) and study quality 
was not assessed systematically. We found no other systematic reviews or meta-analyses of individual herpesvi-
ruses and dementia. Two cohort studies from Taiwan using the National Health Insurance Database published 
after the dates of our search strengthened our findings. One study reported that herpes zoster was associated with 
a small increase in subsequent dementia risk – adjusted HR 1.11; 95% CI, 1.04–1.1777. The other assessed the 
association between clinical presentation of new HSV symptoms (either oral or genital) and dementia in patients 
aged ≥50 years and found an increased risk of incident dementia (adjusted HR 2.56; 95% CI, 2.35–2.80), although 
the effect was attenuated after removing dementia diagnoses made in the first year after HSV, which were unlikely 
to be causally linked (adjusted HR 1.65; 95% CI; 1.44–1.87)78. In both studies, antiviral prescriptions after herpes-
virus diagnosis were associated with lower dementia rates, although this warrants further investigation.
Our findings that larger longitudinal studies supported a possible association between CMV and dementia or 
cognitive decline are also consistent with literature highlighting the role of CMV in stimulating ‘inflammaging’ – 
a state of low-grade chronic inflammation occurring in older individuals which predisposes to a range of adverse 
health outcomes79. Several studies have investigated the effect of infectious burden on cognition. Cross-sectional 
analyses show that a greater infectious burden, measured by IgG seropositivity to a range of antigens (includ-
ing but not limited to herpesviruses), is associated with poorer cognitive performance in young to middle-aged 
adults80 and with MCI in older adults81 after adjusting for sociodemographic and clinical confounders. One lon-
gitudinal study showed a similar association between infectious burden and cognitive decline in the memory 
domain82.
Our review highlights the complexity of studying the effects of viruses typically acquired in childhood on 
syndromes such as MCI and dementia, which have long latent periods and are associated with subtle behavioural, 
nutritional and immune changes that may occur many years before diagnosis. Nevertheless, knowledge of the 
mechanisms triggering dementia onset remains limited. Herpesviruses are common and a potentially tractable 
target for prevention with vaccines or treatment: the alpha herpesviruses (HSV-1, HSV-2 and VZV) in particular 
have rapid replication cycles and are susceptible to antiviral agents such as the synthetic nucleoside analogue 
acyclovir and related drugs. Although no effect of antiviral therapy on cognitive outcomes was seen in an RCT 
conducted in a population with herpes simplex encephalitis72, cognitive sequelae may be driven by encephalitis 
itself rather than any original causative organism83. The effect of antiviral therapy on cognitive outcomes in other 
8Scientific RepoRts |          (2019) 9:4743  | https://doi.org/10.1038/s41598-019-41218-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
HSV infected populations therefore remains unclear. While genetically influenced, herpesvirus acquisition is also 
socially-patterned, e.g. for CMV, individuals of lower socio-economic status are more likely to become infected 
earlier and to have higher antibody titres throughout life77, possibly reflecting a greater propensity to reactivation.
Future research should focus on high quality population studies using longitudinal designs to investigate 
effects of infections on long-term health outcomes such as dementia, ideally using repeated measures taken across 
the life course. For studies of herpesviruses, methods and timing of measurement are critical; strategies may 
include active surveillance in population cohort studies for viruses under-reported in electronic health records. 
For maximum benefit to policymakers and clinicians, future research should seek to understand when and in 
whom herpesvirus reactivation is associated with greatest risk of adverse health outcomes, to guide targeted 
intervention strategies.
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